Celltrion's 'Rekkirona' Selected by EMA as 'COVID-19 Emergency Medicine'

Celltrion's COVID-19 Antibody Treatment 'Rekkirona'

[Asia Economy Reporter Chunhee Lee] Celltrion's COVID-19 antibody treatment 'Rekkirona' (generic name 'Regdanvimab') has been selected for the list of 'critical medicines' for the COVID-19 Public Health Emergency (PHE) by the Medicines Shortages Steering Group (MSSG) under the European Medicines Agency (EMA).

According to related industries on the 9th, the MSSG announced on the 7th (local time) a list of critical medicines encompassing vaccines and treatments approved within the European Union (EU) for the prevention or treatment of COVID-19.

The list includes five vaccines and nine treatments. The vaccines selected are ▲Comirnaty (Pfizer vaccine) ▲Jcovden (Janssen vaccine) ▲Nuvaxovid (Novavax vaccine) ▲Spikevax (Moderna vaccine) ▲Vaxzevria (AstraZeneca vaccine). The treatments include ▲medicines containing dexamethasone ▲Evusheld ▲Kineret ▲Paxlovid ▲Rekkirona ▲Actemra ▲Ronapreve ▲Veklury (generic name 'Remdesivir') ▲Xevudy (generic name 'Sotrovimab').

The EMA explained, "This list includes all COVID-19 vaccines and treatments approved in the EU," adding, "The list will be subject to change depending on pandemic developments such as shortages of specific medicines or approval of new medicines."

The demand and supply situation of these medicines will be monitored by the EMA going forward. Marketing Authorization Holders (MAHs) of these medicines must regularly report to the EMA on supply and demand forecasts as well as potential or actual shortages. Additionally, EU member states must regularly report the expected demand for these medicines by country.

This content was produced with the assistance of AI translation services.